chrisvoncsefalvay/vaers-outcomes huggingface dataset:
a slight cough/ dry cough; scratchy throat; This is a spontaneous report from a contactable female consumer (patient) reported for herself via Medical Information Team. A 58-year-old female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: Unknown), via an unspecified route of administration on 15Apr2021 as dose 1, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. She stated that she was due for her second dose of the Pfizer Covid 19 vaccine today but she has a slight cough/dry cough and scratchy throat; she have like a little tickling. She was due to get her second one. She was due to take it today that's why she was calling to ask should she still take it as her throat was scratchy and she have a slight cough. Asking if she should take her second dose of the vaccine. The outcome of events was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
A 74 y.o. female patient of MD with history of Tremor, neuropathy, T2DM, Hx of breast Ca,  presented to  Hospital with Cough, SOB, Fever   Sepsis COVID19 pneumonia Acute hypoxic respiratory failure 2 days duration of feeling sick, persistent cough productive of greenish/ streaked  blood sputum and SOB Fever, high temp of 100.9, leukocytosis of 12, lactic acid of 3.3, tachycardia, CXR non acute, 02 sat 88, requiring 2 lit NC 02 Immunized x3 will hold further IV abx for now Continue steroids and remdesivir IS/PEP, Mucinex, continues pulse ox Lactate now WNL CRP now improving Weaned to room air and discharged with prescription to complete course of decadron   AKI on CKD stage 3 Cr 1.5 Has received IV fluids in ER Tolerating PO Creatinine improved Monitor U/O and renal parameters   T2DM with hyperglycemia Last A1c 6.5   Hyperlipidemia Continue home atorvastatin   Diabetic polyneuropathy Trigeminal neuralgia Resume carbamazepine and gabapentin   Depression/Anxiety Continue home buspar and remeron
Red swelling like a bump; This spontaneous case was reported by a consumer and describes the occurrence of ERYTHEMA (Red swelling like a bump) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Feb-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (Red swelling like a bump). At the time of the report, ERYTHEMA (Red swelling like a bump) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 03-May-2021: The event outcome was updated as recovering.
Contracted Covid in January 2023; little sore at site of vaccines; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Contracted Covid in January 2023) and VACCINATION SITE PAIN (little sore at site of vaccines) in a 63-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     Previously administered products included for Product used for unknown indication: MEASLES VACCINE;MUMPS VACCINE;RUBELLA VACCINE;VARICELLA ZOSTER VACCINE in 2022, PNEUMOCIN [PNEUMOCOCCAL VACCINE] in 2022 and FLU [INFLUENZA VACCINE] in 2022. Past adverse reactions to the above products included No adverse event with FLU [INFLUENZA VACCINE], MEASLES VACCINE;MUMPS VACCINE;RUBELLA VACCINE; andVARICELLA ZOSTER VACCINE and PNEUMOCIN [PNEUMOCOCCAL VACCINE]. Concurrent medical conditions included Type 2 diabetes mellitus (Controlled) since 2019.    In September 2022, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In September 2022, the patient experienced VACCINATION SITE PAIN (little sore at site of vaccines). In January 2023, the patient experienced COVID-19 (Contracted Covid in January 2023). At the time of the report, COVID-19 (Contracted Covid in January 2023) outcome was unknown and VACCINATION SITE PAIN (little sore at site of vaccines) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood pressure measurement: Low.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication details was reported. No treatment medication details was reported.  It was reported that after bivalent booster patient experienced No fever and had Stomach issues (was in the bathroom a lot). Lasted about 1 week. After that week, Patient felt better than before Patient contracted Covid. Patient said that his vaccines and boosters were working to fight off the virus and very happy with Moderna products. Patient stated that patient had these same symptoms in 2019 before patient ever hear of Covid, and thinks it may had been Covid then as well. Patient received 2 primary doses of Moderna Vaccine around March 2021, received his first booster December 2021. In September 2022 patient received the Bivalent booster. Loves Moderna products, because patient hardly gets any side effects, his arm may have been a little sore at site of vaccines and booster, Patient had no other side effects.   Reporter did not allow further contact
This spontaneous report as received from a registered nurse refers to unspecified number of patients of unknown age and gender. No concurrent conditions, medical history, allergy/drug reactions and concomitant medications were reported. On an unknown date, the patients were vaccinated with improperly stored ROTATEQ lot # M041765 with expiry date: 05-MAY-2018 and lot#M045546 with expiry date: 12-JUN-2018 (dosing details, anatomical location were unknown) orally for prophylaxis.  It was reported that the vaccines were exposed to a temperature range of 9C to 25C (9.9C) for a duration of 13 hours and 15 minutes. During previous temperature excursion vaccines were exposed to a temperature range of 9C to 25C (11.5C) for 7 hours and 45 minutes. Data logger was involved. No adverse symptoms were reported. There were no product quality complaints (PQC) involved.  This is one of several reports received from the same reporter.; Sender's Comments: US-009507513-1708USA009615:
BLISTERY RASH ON LOWER RIGHT SIDE OF BACK.  PAINFUL TO THE TOUCH.
Patient developed Shingles- diagnosed by nurse practioner at the little clinic. Patient believed it may have been from the vaccine.
I used to have severe childhood asthma - haven't had an attack in 40 years.  Since having the vaccine - I have experienced a lot of 'chestiness' and vastly worse flu on x3 separate occasions than I am used to having.
Pt received flu and pneumonia vac 11/4/03 PM. On 11/5/03 AM pt noted redness. Reported to health dept. Pt seen by PA 11/5/03 PM for F/U evaluation. Antihistamine Rx given. Red area marked. Pt to return if redness increased. Redness did increase. Pt returned. They Rx Keflex and to continue antihistamine and return if no improvements. Pt stopped into health dept. Will call HD if further concerns.
Information has been received from a physician concerning a 17 year old male patient who on 02-DEC-1993 was vaccinated with the first dose of MMR II. On 09-OCT-1994, the patient received the second dose of MMR II. On 17-NOV-2009 laboratory diagnostic tests were performed: IgG 7.63; and serum amylase test: 361. On 17-NOV-2009, the patient was diagnosed and was afebrile. It was reported that on 25-NOV-2009 the patient experienced mumps outbreak. The outcome of the patient was not reported. Follow up information has been received from the physician who reported that the 17 year old patient (also reported as 16 year old at onset date) experienced mumps on 14-NOV-2009 (previously reported as on 25-NOV-2009). The date diagnosed was reported as 16-NOV-2009 (previously reported as 17-NOV-2009). The patient was afebrile and experienced parotitis. On 16-NOV-2009, the blood work test showed IgM negative, IgG 5.46 and serum amylase 317. At the time of the report the patient's outcome was unknown. No further information is available.
After receiving 1st Moderna COVID19 vaccine and while waiting during the 15min waiting period, patient saw someone else get anxious and wobbly and need to lay down, then he also got anxious and felt like his vertigo had been triggered... dizzy when turning head to the side, which he gets sometimes, but this started for him after vaccination. Laid down, rested, and felt better-- symptoms resolved and he was discharged to home. Noted to be hypertensive 143/93-- discussed with him and asked him to speak with primary care physician.
Right arm & side numbness, pins & needles feeling Lost of strength in right hand Itching sensation on right side of neck
Vaccine administered after more than 1 temperature excursion; Vaccine administered after more than 1 temperature excursion; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 030B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 03-Apr-2021 at 1:43 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 03-Apr-2021 at 1:43 PM,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Vaccine administered after more than 1 temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Vaccine administered after more than 1 temperature excursion) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Age of the patient was reported as 39.09.  Concomitant medication of the patient was not reported.  Batch number 030B21A underwent temperature excursion on 03-Apr-2021 with temperature of 34 degrees Fahrenheit at 09:00 AM. These vials were moved to fridge on 30-Mar-2021 and beyond use date for the vials was reported as 29-Apr-2021. The vaccines moved to clinic on 03-Apr-2021. Storage condition at the time of the excursion was cooler storage during high-pace COVID-19 vaccination clinic.  Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination. Vials were only punctured right before administration. Vaccines were not frozen at time of administration and prior to administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34 or 35 degree Fahrenheit. The reporter reported that, no data logger reports were available and fisher brand traceable temperature monitor was used to record hourly temperatures.  No treatment information was provided by the reporter.
Redness at injection site. Redness moved down arm to elbow and became painful. Patient sought medical treatment. Md treating as cellultis with antibiotics and steroids.
My first shot  was just a red spot around the shot area that was the size of a quarter and only lasted about 3 days.  My second shot, produced itchiness  on my arm below shot area to elbow for several days    7-8days
About 18 hours after, had a bad headache, nausea and some muscle pains which proceeded to get worse for the next several hours, confining me to bed until 24 hours later. Also chills and sweating.
Felt fine immediately after the vaccination. Later in the evening around 11pm, my body felt achy. I had very little energy, and felt cold despite a warm temperature in my house. I woke up the next morning feeling an entire body ache and minor pain at the injection site.
Informaiton has been received from an office manager referring to an unspecified number of patients of unknown age and gender. On unspecified dates, the patients were vaccinated with improperly stored doses of GARDASIL (lot # K006960, expiration date 19-FEB-2017 and/or lot# L006549, expiration date 06-APR-2017, dose and route not provided (Incorrect product storage). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
I went into my get my flu shot from this location as it it required by my work in order to keep my job. I did not look when the nurse gave my the flu vaccine as it causes me to become lightheaded and pass out. I noticed during the vaccination that it oddly didn't hurt like a usual flu vaccine. I noticed when she put the band-aid on that the flu vaccine was given very high, almost up to my shoulder bone. I came home and it hurt worse than usual, but I thought the pain would go away in a day or so. The pain didn't go away. Instead, for the next week, it kept getting worse. It got to the point where I could not sleep on the left side anymore because my shoulder hurts so bad.  I have dull, aching pain in my left shoulder constantly. The pain starts at where the vaccine was given and radiates down my arm into my elbow. It it made worse by doing any activity with my left arm, even simple things. After a week of pain, I made an appointment at my primary care physician and she said that the pain was caused from the flu vaccine shot being given too high in my left arm. She started me on a dose of steroids as she said that my shoulder was inflamed and swollen and told me to come back to reassess after the steroids were finished. My left arm is still hurting and I will need to seek further treatment.
The Moderna booster she says was given June 15, 2022 upper left arm. She reportsaAbout 6 hours later her pain 10 radiated down to her fingers, caused severe nerve issues and is seeing physical therapy due to the shot causing "covid arm". She said she had reported the SE the next day to a nurse. She had iced it. normal SE hot, red to touch and went away but the nerve pain down to her fingers is not normal and not sure if VARS was completed. She requested we complete the CDC incident report if not done yet. She requested us know it is real, report to cdc and to teach injection site placement.
began running low grade fever 14OCT96 approx 1 day later on 15OCT96 had sz; transported to ER per EMS temp @ that time was 105 & was adm overnoc for observation;but noted appetite not up to par;
# 3 booster received on 11/12. Fever (100.8), chills, nausea, weakness and fatigue on 11/13. Developed red rash from armpits down both sides to waist and on upper thighs across to pubic area. Symptoms and rash resolved by 11/15 without treatment.
This spontaneous report was received from a pharmacist and refers to a 56 year old female patient (a pharmacy technician at the pharmacy) with unknown reaction or allergies to morphine. There was no patient's pertinent medical history and concomitant medications reported. On 02-NOV-2015, the patient was vaccinated with ZOSTAVAX injection (lot# reported as L032399, expiration date 26-NOV-2016) single dose, subcutaneously in the left upper arm. On 03-NOV-2015, the patient experienced a large area of redness and warmth at the injection site. The area of reaction was also slightly itchy. The patient was treated with unspecified antihistamines. On 12-NOV-2015, the patient recovered from the events. The patient sought medical attention and spoke with the pharmacist. The relatedness between the events and ZOSTAVAX was not reported. Additional information is not expected, as there was no consent for follow up.
red rash covering the left upper arm, the arm where her covid vaccine was given. treated with a 6 day round of prednisone due to the vast area of the red rash covering her whole left upper arm.
Swelling in injection site, rash on top of hand, a little of rash above lip - sx started day after immunization by day 3 rash, somewhat better and so is swelling.
patient had chest pain starting one day after second Pfizer covid19 vaccine . Chest pain lasted 2 days. she has since (8 weeks) had chest pressure (constant) and shortness of breath with any increased activity (stairs). She can no longer run more than a couple of minutes without stopping to rest.  Referral to pediatric cardiologist pending.
Immunizations given in the morning. Developed high fever (104) later that evening and patient had a short seizure lasting a few seconds.
extremely sore / achiness; red arm; fever; This spontaneous case was reported by a physician and describes the occurrence of MYALGIA (extremely sore / achiness), ERYTHEMA (red arm) and PYREXIA (fever) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 030L20A and 002A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 23-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MYALGIA (extremely sore / achiness), ERYTHEMA (red arm) and PYREXIA (fever). At the time of the report, MYALGIA (extremely sore / achiness), ERYTHEMA (red arm) and PYREXIA (fever) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 31-May-2021, SARS-CoV-2 antibody test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) and mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   no concomitant drugs included  no treatment drugs included   This case was linked to MOD-2021-209538 (Patient Link).
Chief Complaint: Shortness of Breath Additional Medical History:  History ofThis is a 43-year-old female of sarcoidosis on prednisone and methotrexate who presents to the emergency department with several days of dyspnea.  Patient was diagnosed with COVID-19 on 11/11/2021.  She had some transient improvement now is having worsening of her symptoms that she is extremely short of breath with nonproductive cough she is having some wheezing she describes severe exertional dyspnea gets out of breath if she tries to walk across the room.  Her sarcoidosis is treated by a pulmonologist.  She says she also has a cardiologist as she has had a rapid heart rate in the past and she thinks possibly congestive heart failure she is uncertain of the exact tachyarrhythmia.
PERIPHERAL NEUROPATHY 1/6/2023  -- RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Very sore muscles at injection site 1 hr. later, 10 hrs. later woke up with fever, chills, shaking, headache. Lasted for about 3 hrs. I took 2, 200mg, ibuprofen for headache and chills then went to sleep. In the morning I was ok but my arm was still very sore.
Patient states "pain in left deltoid shot up my neck". No swelling at site; patient waited in hall additional 15 minutes and during this time began to complain of "tongue swelling and cannot swallow". EpiPen 0.3 mg administered in right thigh through clothes. 911 called. Vital signs taken. EMS arrived at 1:50 pm.  Patient escorted by EMS to truck for evaluation and care transferred to EMS.
Patient received the PNEUMOVAX and FLUZONE HD on Thursday 09/20/12 in the same arm. Patient reported that once he went home after about 30 minutes after receiving the shots that he got a extremely bad headache and eventually nausea. This lasted for 3 days and he was bed-ridden. A rash started developing at the site administration as well. Rash was still present on day 4. Since the pharmacist placed both shots in the arm - patient preference at the time of administration, we are unable to tell which shot caused this or if the combination of the two caused it. Patient has never a reaction to a shot before. Patient was referred to primary care.
This is spontaneous case, reported by healthcare professional (non-other) to VAERS and initially retrieved on 03-Feb-2018 by Seqirus from VAERS (VAERS ID: 724391), concerns a 48-year-old, adult female patient. The patient's historical condition included spinal post-concussion (motion and light sensitivity). The patient's current condition was not reported. The patient's concomitant medications included loratadine, progesterone, Estradiol, multivitamin, Gamma-aminobutyric acid, 5HTP, flaxseed oil, vitamin D, vitamin B, reservatrol and Curcumin for an unknown indication. On 03-Oct-2017, the patient was administered with influenza vaccine (route of administration: injection, anatomical location: left arm, dose, manufacturer, trade name, batch number and expiry date: not reported). On 04-Oct-2017, after 1 day of vaccination, that patient had whole body pain and mild fever. The patient had sore throat and pus nodules were visible in her throat. It was reported that, the patient never experienced fever and pus nodules in throat with previous vaccination. It was reported that, patient had not consulted the physician. No lab test was done. At the time of this report, the patient had not yet recovered from the events. The reporter assessed this case as non-serious. Non-significant case correction received with IRD 03-Feb-2018: The statement in the narrative was corrected from 'in throat before in previous vaccination' to 'in throat with previous vaccination'. The narrative was amended accordingly.
This case was reported by a other health professional via call center representative and described the occurrence of local reaction in a 15-year-old male patient who received FLUARIX QUADRIVALENT (batch number ZG3S5, expiry date 6th June 2017). Previously administered products included Flumist (received with no previous reports of reaction). On 26th October 2016, the patient received FLUARIX QUADRIVALENT. In October 2016, less than a week after receiving FLUARIX QUADRIVALENT, the patient experienced local reaction, malaise, fever and general body pain. The patient was treated MEDROL. On an unknown date, the outcome of the local reaction and malaise were recovered/resolved and the outcome of the fever and general body pain were unknown. It was unknown if the reporter considered the local reaction, malaise, fever and general body pain to be related to FLUARIX QUADRIVALENT. Additional details were reported as follows: The case was received from Certified Medical Assistant. The patient received a dose of FLUARIX QUADRIVALENT (preservation-free GSK flu vaccine) and one day after vaccination developed 5.5 inch localized reaction, low-grade fever, malaise and body aches. The patient's mother reported to the office the following day after administration that the reactions had occurred but the exact time frame of when reactions began was unknown. The patient had a follow up appointment with the nurse practitioner. The patient was unable to receive Flumist again due to his age and was administered FLUARIX QUADRIVALENT instead, which led to wrong vaccine administered. No further information was reported regarding the event.
Pt seen on 01/05/05 for painful/itchy rash on left arm x 1wk; afebrile. Vesicular lesions with some drying/crusting diagnosis: shingles
Pt is not the correct age to get a high dose flu shot. Nurse gave the medication.